ImmunoSensation - the immune sensory system

Ann Hepatol. 2013 Feb 11.

Prediction of minimal residual viremia in HCV type 1 infected patients receiving interferon-based therapy.

Knop V, Teuber G, Klinker H, Möller B, Rasenack J, Hinrichsen H, Gerlach T, Spengler U, Buggisch P, Neumann K, Sarrazin C, Zeuzem S, Berg T

Complete suppression of viral replication is crucial in chronic HCV treatment in order to prevent relapse and resistance development. We wanted to find out which factors influence the period from being already HCV RNA negative by bDNA assay (< 615 IU/mL) to become undetectable by the more sensitive TMA test (< 5.3 IU/mL).

PMID: 23396729